102 related articles for article (PubMed ID: 3593602)
1. [Antitumor effect of bromocriptine on estrogen-induced rat prolactinomas: special reference to changes in secretory granules by stereological analysis].
Saitoh Y; Koizumi K; Arita N; Hayakawa T; Aono T; Matsumoto K; Mogami H; Mori H
No To Shinkei; 1987 Apr; 39(4):347-54. PubMed ID: 3593602
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of bromocriptine on estrogen-induced rat prolactinomas: ultrastructural alterations of secretory granules.
Saitoh Y; Koizumi K; Arita N; Hayakawa T; Mogami H; Matsumoto K; Mori H
Anticancer Res; 1986; 6(5):1149-55. PubMed ID: 3800323
[TBL] [Abstract][Full Text] [Related]
3. Cytosuppressive effect of bromocriptine on human prolactinomas: stereological analysis of ultrastructural alterations with special reference to secretory granules.
Saitoh Y; Mori S; Arita N; Hayakawa T; Mogami H; Matsumoto K; Mori H
Cancer Res; 1986 Mar; 46(3):1507-12. PubMed ID: 3943108
[TBL] [Abstract][Full Text] [Related]
4. Decreased prolactin level in secretory granules and their increased exocytosis in estrogen-induced pituitary hyperplasia in rats treated with a dopamine agonist.
Maeda T; Sawada K; Itoh Y; Moriwaki K; Mori H
Lab Invest; 1991 Dec; 65(6):679-87. PubMed ID: 1753713
[TBL] [Abstract][Full Text] [Related]
5. Ultrastructural localization of prolactin in estrogen-induced prolactinoma of the rat pituitary. Experimental models for the human prolactinomas and the effects of bromocriptine.
Osamura RY; Watanabe K
Acta Pathol Jpn; 1986 Aug; 36(8):1131-7. PubMed ID: 3776530
[TBL] [Abstract][Full Text] [Related]
6. Changes in prolactinomas and somatotropinomas in humans treated with bromocriptine.
Mori H; Maeda T; Saitoh Y; Onishi T
Pathol Res Pract; 1988 Sep; 183(5):580-3. PubMed ID: 3237547
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.
Niwa J; Minase T; Hashi K; Mori M
Virchows Arch B Cell Pathol Incl Mol Pathol; 1987; 53(2):89-96. PubMed ID: 2887062
[TBL] [Abstract][Full Text] [Related]
8. Ultrastructural localization of prolactin in the human pituitary prolactinomas and its changes by bromocriptine treatment.
Osamura RY; Teramoto A; Watanabe K
Acta Pathol Jpn; 1986 Aug; 36(8):1123-30. PubMed ID: 3776529
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical, electron microscopic, and morphometric studies of human prolactinomas after short-term bromocriptine treatment.
Niwa J; Minase T; Mori M; Hashi K
Surg Neurol; 1987 Nov; 28(5):339-44. PubMed ID: 3660204
[TBL] [Abstract][Full Text] [Related]
10. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors.
Barrow DL; Tindall GT; Kovacs K; Thorner MO; Horvath E; Hoffman JC
J Neurosurg; 1984 Jan; 60(1):1-7. PubMed ID: 6689702
[TBL] [Abstract][Full Text] [Related]
11. Storage and release of secretory granules in human prolactinomas: modification by bromocriptine.
Landolt AM; Osterwalder V; Landolt TA
J Endocrinol; 1987 Jun; 113(3):495-9. PubMed ID: 3625099
[TBL] [Abstract][Full Text] [Related]
12. [Pathological changes of prolactinomas treated with bromocriptine].
Teramoto A; Takakura K; Fukushima T; Osamura Y
No Shinkei Geka; 1982 Jun; 10(6):619-27. PubMed ID: 7121729
[TBL] [Abstract][Full Text] [Related]
13. In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors.
Eguchi K; Kawamoto K; Uozumi T; Ito A; Arita K; Kurisu K
Endocr J; 1995 Apr; 42(2):153-61. PubMed ID: 7627259
[TBL] [Abstract][Full Text] [Related]
14. Effects of chronic bromocriptine treatment of an estrone-induced, prolactin-secreting rat pituitary adenoma.
Eljarmak D; Lis M; Cantin M; Carrière PD; Collu R
Horm Res; 1985; 21(3):160-7. PubMed ID: 3997065
[TBL] [Abstract][Full Text] [Related]
15. Rapid regression of pituitary prolactinomas during bromocriptine treatment.
Thorner MO; Martin WH; Rogol AD; Morris JL; Perryman RL; Conway BP; Howards SS; Wolfman MG; MacLeod RM
J Clin Endocrinol Metab; 1980 Sep; 51(3):438-45. PubMed ID: 6773972
[TBL] [Abstract][Full Text] [Related]
16. Increased exocytosis of secretory granules in contrast to reduced serum hormone levels in pituitary adenomas of humans and rats treated with dopamine agonist.
Mori H; Saitoh Y; Maeda T; Okada Y; Hirano H; Tsuji M
Med Electron Microsc; 2001 Jun; 34(2):123-33. PubMed ID: 11685661
[TBL] [Abstract][Full Text] [Related]
17. Necrotic changes in prolactinomas after long term administration of bromocriptine.
Gen M; Uozumi T; Ohta M; Ito A; Kajiwara H; Mori S
J Clin Endocrinol Metab; 1984 Sep; 59(3):463-70. PubMed ID: 6746860
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
Xiao Z; Yang X; Zhang K; Liu Z; Shao Z; Song C; Wang X; Li Z
Int J Med Sci; 2020; 17(18):3174-3189. PubMed ID: 33173437
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-induced prolactinoma in a man.
Gooren LJ; Assies J; Asscheman H; de Slegte R; van Kessel H
J Clin Endocrinol Metab; 1988 Feb; 66(2):444-6. PubMed ID: 3339116
[TBL] [Abstract][Full Text] [Related]
20. [Morphological studies on estrogen-induced PRL cell hyperplasia in rat pituitary gland--immunocytochemical and scanning electron microscopic studies].
Inagaki H; Hori T
No To Shinkei; 1989 Jun; 41(6):593-601. PubMed ID: 2803826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
